Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis

Aging Clinical and Experimental Research

Volumn 12, Issue 1, 2000, Pages 1-12

  Schnitzer, T ^b   Bone, H G ^b   Crepaldi, G ^b   Adami, S ^b   McClung, M ^b   Kiel, D ^b   Felsenberg, D ^b   Recker, R R ^b   Tonino, R P ^b   Roux, C ^b   Pinchera, A ^b   Foldes, A J ^b   Greenspan, S L ^b   Levine, M A ^b   Emkey, R ^b   Santora II, A C ^b   Kaur, A ^b   Thompson, D E ^b   Yates, J ^b   Orloff, J J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

Alendronate; Bone mass; Once weekly dosing; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; COLLAGEN TYPE 1; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; GASTROINTESTINAL TOXICITY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSSIFICATION; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0034097152     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339822     Document Type: Article

References (37)

1. Greenberg R.N.: Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 6: 592-599, 1984.
2. Lau H.S., Beuning K.S., Postma-Lim E., Klein-Beemink L., de Boer A., Porsius A.J.: Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharmacy World Sci. 18: 63-68, 1996.
3. Venturini F., Nichol M.B., Sung J.C., Bailey K.L., Cody M., McCombs J.S.: Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann. Pharmacother. 33: 281-288, 1999.
4. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W. Jr., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C. II, Lombardi A., Shah R., Hirsch L.J., Karpf D.B.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333: 1437-1443, 1995.
5. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K. E.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541, 1996.
6. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineus R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., LaCroix A.Z.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280: 2077-2082, 1998.
7. Pols H.A.P., Felsenberg D., Hanley D.A., Stepan J., Munoz-Torres M., Wilkin T.J., Qin-sheng G., Galich A.M., Vandormael K., Yates A.J., Stych B.: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos. Int. 9: 461-468, 1999.
8. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates A.J.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N. Engl. J. Med. 338: 485-492, 1998.
9. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., El Hajj Fuleihan G., Reda C., Yates A.J., Ravn P.: Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann. Intern. Med. 128: 253-261, 1998.
10. Bauer D.C., Black D., Ensrud K., Thompson D., Hochberg M., Nevitt M., Musliner T., Freedholm D.: Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch. Intern. Med. 2000 (in press).
11. Seedor J.G., Quartuccio H.A., Thompson D.D.: The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Min. Res. 6: 339-346, 1991.
12. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D., Quartuccio H.A., Fioravanti C., Clair J., Brown E., Hayes W.C., Rodan G.A.: The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92: 2577-2586, 1993.
13. Rodan G.A., Seedor J.G., Balena R.: Preclinical pharmacology of alendronate. Osteoporos. Int. Suppl. (3): S7-12, 1993.
14. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., Beneton M.N., Gertz B.J., Sciberras D.G., Holland S.D., Orgee J., Coombes G.M., Rogers S.R., Porras A.G.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12: 1700-1707, 1997.
15. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G.: Clinical pharmacology of alendronate sodium. Osteoporos. Int. Suppl. (3): S13-16, 1993.
16. Porras A.G., Holland S.D., Gertz B.J.: Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36: 315-328, 1999.
17. Lufkin E.G., Argueta R., Whitaker M.D., Cameron A.L., Wong V.H., Egan K.S., O'Fallon W.M., Riggs B.L.: Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos. Int. 4: 320-322, 1994.
18. Chestnut C.H., McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D., Kher U., Pryor-Tillotson S., Santora A.C.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am. J. Med. 99: 144-152, 1995.
19. DeGroen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335: 1016-1021, 1996.
20. Siris E.S., Chines A.A., Altman R.D., Brown J.P., Johnston C.C. Jr., Lang R., McClung M.R., Mallette L.E., Miller P.D., Ryan W.G., Singer F.R., Tucci J.R., Eusebio R.A., Bekker P.J.: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J. Bone Miner. Res. 13: 1032-1037, 1998.
21. Saunders R.L.: Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome. South Med. J. 70: 1327-1329, 1977.
22. Peter C.P., Handt L.K., Smith S.M.: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig. Dis. Sci. 43: 1998-2002, 1998.
23. Bone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., Prahalada S., Daifotis A., Orloff J., Yates A.J.: Weekly administration of alendronate: rationale and plan for clinical assessment. Clin. Ther. 22: 15-28, 2000.
24. Black D.M., Palermo L., Nevitt M.C., Genant H.K, Epstein R., San Valentin R., Cummings S.R.: Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures. J. Bone Miner. Res. 10: 890-902, 1995.
25. Faulkner K.G., McClung M.R.: Quality control of DXA instruments in multicenter trials. Osfeoporos. Int. 5: 218-227, 1995.
26. Genant H.K., Wu C.Y., van Kuijk C., Nevitt M.C.: Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8: 1137-1148, 1993.
27. Devogelaer J.P., Broll H., Correa-Rotter R., Cumming D.C., De Deuxchaisnes C.N., Geusens P., Hosking D., Jaeger P., Kaufman J.M., Leite M., Leon J., Liberman U., Menkes C.J., Meunier P.J., Reid I., Rodriguez J., Romanowicz A., Seeman E., Vermeulen A., Hirsch L.J., Lombardi A., Plezia K., Santora A.C., Yates A.J., Yuan W.: Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18: 141-150, 1996.
28. Adami S., Passeri M., Ortolani S., Broggini M., Carratelli L., Caruso I., Gandolini G., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Pryor-Tillotson S., Reda C., Romanini L., Subrizi D., Wei L., Yates A.J.: Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17: 383-390, 1995.
29. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F.: Trials to assess equivalence: the importance of rigorous methods. Br. Med. J. 313: 36-39, 1996.
30. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 18: 1905-1942, 1999.
31. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sorensen O.H.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322: 1265-1271, 1990.
32. Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C. III, Yanover M.J., Mysiw W.J., Kohse L., Rao M.B., Steiger P., Richmond B., Chestnut C.H.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323: 73-79, 1990.
33. Marshall D., Johnell O., Wedel H.: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. B. M. J. 312: 1254-1259, 1996.
34. Hochberg M., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., Barrett-Connor E., Musliner T., Thompson D.: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 42: 1246-1254, 1999.
35. Wasnich RD, Miller PD.: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab. 85: 231-236, 2000.
36. Garnero P., Sornay-Rendu E., Delmas P.D.: Decreased bone turnover in oral contraceptive users. Bone 16: 499-503, 1995.
37. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J.: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100: 1475-1480, 1997.